Developer docs
API playgroundTry for free, no card

Search company profiles

Medivir

Full company profile

uuid0005vnt

Namestring
Medivir
Legal namestring
Medivir AB (publ)
Websiteurl
medivir.com
Company typeenum
Public
Founded yearint
1988
Descriptiontext

Medivir AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 1988 and headquartered in Huddinge, Sweden, listed on Nasdaq Stockholm's Small Cap segment under ticker MVIR. The company develops innovative therapies targeting areas of high unmet medical need, with a current research focus on oncology — specifically hepatocellular carcinoma (HCC) via its proprietary candidate fostroxacitabine bralpamide (fostrox) — and on rare bone disorders including osteogenesis imperfecta and Legg-Calvé-Perthes disease via MIV-711, a cathepsin K inhibitor. Fostrox is a liver-targeted oral prodrug of troxacitabine that selectively delivers a DNA polymerase inhibitor to liver tumors while sparing healthy hepatocytes, with patent protection extending to April 2041; MIV-711 is positioned as a potential first-in-class disease-modifying treatment for OI with dual effects on bone resorption and formation.

Medivir operates a hybrid business model combining proprietary drug development toward commercialization in specialty/rare-disease markets with limited prescriber bases and out-licensing of pipeline assets to larger partners for development and commercialization in broader indications. Revenue is generated through licensing royalties — primarily from GSK's sales of Xerclear/Zoviduo (cold sore treatment out-licensed in 2009) — and from milestone and royalty entitlements on out-licensed assets including remetinostat (Biossil Inc., up to USD 60M in potential milestones plus mid-single-digit royalties), MIV-701/VBX-1000 (Vetbiolix, veterinary periodontitis), MBLI/MET-X (INFEX Therapeutics), and USP-7 (Ubiquigent). The company has secured FDA Orphan Drug Designation for fostrox (HCC, 2020), FDA/EMA orphan and Rare Pediatric Disease Designations for MIV-711 across multiple indications (2025), and a clinical collaboration with Eisai to evaluate fostrox in combination with Lenvima in second-line HCC.

Short descriptiontext

Medivir AB is a Swedish clinical-stage pharmaceutical company developing proprietary drug candidates for hepatocellular carcinoma (fostrox) and rare bone disorders (MIV-711), supplemented by out-licensed assets generating royalty and milestone income, with proprietary programs protected by multiple FDA/EMA orphan drug designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHuddinge, Sweden
HQ citystring
Huddinge
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical drug development, oncology therapeutics, hepatocellular carcinoma treatment, rare disease therapeutics, pharmaceutical out-licensing
Industry2 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Royalties from Xerclear/Zoviduo
TypeLicensing Royalties
Description

Medivir receives royalties on sales of Xerclear/Zoviduo from GlaxoSmithKline and fixed royalties from Shijiazhuang Yuanmai Biotechnology for Chinese sales.

medivir.com
2Remetinostat licensing deal milestones and royalties
TypeLicensing Royalties
Description

Outlicensed remetinostat to Biossil Inc. with potential payments up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.

medivir.com
3MIV-701/VBX-1000 royalties
TypeLicensing Royalties
Description

Medivir retains significant financial upside through future royalties on net sales from Vetbiolix partnership plus substantial share of potential partnership payments from third-party collaborations.

medivir.com
4MBLI/MET-X revenue sharing
TypeLicensing Royalties
Description

Medivir is entitled to a share of potential future revenue from INFEX Therapeutics development of MET-X for resistant bacteria.

medivir.com
5USP-7 revenue sharing
TypeLicensing Royalties
Description

Exclusive global license to Ubiquigent for USP-7 program with agreed revenue sharing upon successful development or commercialization.

medivir.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Medivir is a clinical-stage pharmaceutical company that develops proprietary drug candidates in oncology and rare bone diseases, with lead assets fostrox (a liver-targeted nucleotide DNA polymerase inhibitor prodrug for hepatocellular carcinoma) and MIV-711 (a cathepsin K inhibitor for osteogenesis imperfecta and Legg-Calvé-Perthes disease). It also maintains a portfolio of out-licensed drug assets (Xerclear for labial herpes, Remetinostat for skin cancers, Birinapant for solid tumors, MBLI/MET-X for resistant bacteria, MIV-701/VBX-1000 for veterinary periodontitis, USP-7) that generate royalties and milestone payments from pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ORR of 24% with median DOR of 7 months in Phase 1b/2a fostrox + Lenvima study (21 patients)
+5 more records
Product overview1 text field

Medivir is a Swedish pharmaceutical company focused on developing innovative therapies in areas of high unmet medical need, primarily in oncology. The company's product portfolio consists of proprietary drug candidates in clinical development (fostrox for hepatocellular carcinoma and MIV-711 for osteogenesis imperfecta), projects available for licensing (Birinapant and USP-7), and outlicensed/commercialized products (Xerclear for herpes, MBLI/MET-X for infections, MIV-701 for canine periodontitis, and Remetinostat for skin cancers). Medivir operates either independently or through partnerships for drug development and commercialization.

Product and service4 records
1Fostroxacitabine bralpamide (fostrox)
CategoryProprietary drug candidate
Description

A liver-targeted oral nucleotide DNA polymerase inhibitor prodrug of troxacitabine that selectively delivers the active cell-killing compound to liver tumor cells while minimizing effects on normal liver cells. Being developed for second-line hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, and liver metastases, in combination with lenvatinib.

2MIV-711
CategoryProprietary drug candidate
Description

An oral cathepsin K inhibitor being developed for osteogenesis imperfecta (OI/brittle bone disease), Legg-Calvé-Perthes disease (LCPD), and osteoarthritis. Has demonstrated cartilage preservation and reduction of bone erosion in a Phase II osteoarthritis study and is positioned as a potential first approved pharmacological treatment for OI.

3Birinapant
CategoryLicensing project
Description

An intravenous SMAC mimetic being developed for the treatment of solid tumors, intended to improve treatment response and prolong survival when combined with other pharmaceuticals. Out-licensed to IGM Biosciences.

4USP-7
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Exclusive global licensing agreement for remetinostat development rights. Biossil, a Toronto-based AI-native drug developer, will develop remetinostat globally for cutaneous T-cell lymphoma and other skin cancers. Medivir entitled to up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration for FLEX-HCC investigator-initiated randomized phase 2 study. Dr. Chon serves as primary investigator. Study to be conducted at 8 centers in Korea evaluating fostrox + Lenvima vs Lenvima monotherapy in second-line advanced HCC.

3Eisai Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Clinical trial collaboration and supply agreement for evaluating fostrox in combination with Lenvima (lenvatinib) in a randomized, phase 2b study in second-line advanced liver cancer patients.

medivir.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-02-01
Description

Exclusive global license granted for USP-7 preclinical research program. Ubiquigent to develop and commercialize all related substances in all therapeutic indications in exchange for revenue sharing with Medivir upon successful development or commercialization. Unfortunately, funding challenges have made it impossible for Ubiquigent to continue operations.

5IGM Biosciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Exclusive licensing agreement for birinapant. Birinapant is a SMAC mimetic for treatment of solid tumors, acquired from TetraLogic Pharmaceuticals in 2016.

medivir.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Out-licensed MIV-701 (VBX-1000) for veterinary use in canine and feline periodontitis. Vetbiolix reported positive Proof-of-Concept results in April 2024 and published results in Frontiers in Veterinary Science in November 2025. Phase II study ongoing with results expected Q4 2026. Medivir retains significant financial upside through future royalties and partnership payment sharing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Out-licensed MBLI/MET-X program for addressing resistant bacteria. INFEX received QIDP designation from FDA in 2023 and European patent approval in August 2023. License agreement signed with Venus Remedies Ltd for clinical development in India. Medivir entitled to share of potential future revenue.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2009-01-01
Description

Out-licensed Xerclear marketing rights in Europe and rest of world (excluding China, Israel and South America where Medivir retained rights). Medivir receives royalties on sales of Xerclear/Zoviduo from GSK.

9Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2009-01-01
Description

Out-licensed Xerclear rights for China market. After market registration and production in China, Medivir receives fixed royalty for each unit sold with guaranteed minimum sales during first three years on market.

medivir.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medivir

Pharmaceutical Drug Developmentmedivir.com

Medivir AB is a Swedish clinical-stage pharmaceutical company developing proprietary drug candidates for hepatocellular carcinoma (fostrox) and rare bone disorders (MIV-711), supplemented by out-licensed assets generating royalty and milestone income, with proprietary programs protected by multiple FDA/EMA orphan drug designations.

What Medivir does

Medivir AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 1988 and headquartered in Huddinge, Sweden, listed on Nasdaq Stockholm's Small Cap segment under ticker MVIR. The company develops innovative therapies targeting areas of high unmet medical need, with a current research focus on oncology — specifically hepatocellular carcinoma (HCC) via its proprietary candidate fostroxacitabine bralpamide (fostrox) — and on rare bone disorders including osteogenesis imperfecta and Legg-Calvé-Perthes disease via MIV-711, a cathepsin K inhibitor. Fostrox is a liver-targeted oral prodrug of troxacitabine that selectively delivers a DNA polymerase inhibitor to liver tumors while sparing healthy hepatocytes, with patent protection extending to April 2041; MIV-711 is positioned as a potential first-in-class disease-modifying treatment for OI with dual effects on bone resorption and formation.

Medivir operates a hybrid business model combining proprietary drug development toward commercialization in specialty/rare-disease markets with limited prescriber bases and out-licensing of pipeline assets to larger partners for development and commercialization in broader indications. Revenue is generated through licensing royalties — primarily from GSK's sales of Xerclear/Zoviduo (cold sore treatment out-licensed in 2009) — and from milestone and royalty entitlements on out-licensed assets including remetinostat (Biossil Inc., up to USD 60M in potential milestones plus mid-single-digit royalties), MIV-701/VBX-1000 (Vetbiolix, veterinary periodontitis), MBLI/MET-X (INFEX Therapeutics), and USP-7 (Ubiquigent). The company has secured FDA Orphan Drug Designation for fostrox (HCC, 2020), FDA/EMA orphan and Rare Pediatric Disease Designations for MIV-711 across multiple indications (2025), and a clinical collaboration with Eisai to evaluate fostrox in combination with Lenvima in second-line HCC.

Medivir firmographics

Firmographics
Name
Medivir
Legal name
Medivir AB (publ)
Website
https://medivir.com
Company type
Public
Founded year
1988
Operating status
Operating
Headcount range
11–50 employees
Short description
Medivir AB is a Swedish clinical-stage pharmaceutical company developing proprietary drug candidates for hepatocellular carcinoma (fostrox) and rare bone disorders (MIV-711), supplemented by out-licensed assets generating royalty and milestone income, with proprietary programs protected by multiple FDA/EMA orphan drug designations.
Ownership category
akta.pro rank

Medivir industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Pharmaceutical drug development
  • Oncology therapeutics
  • Hepatocellular carcinoma treatment
  • Rare disease therapeutics
  • Pharmaceutical out-licensing

Where Medivir is headquartered

Location

Headquarters

HQ city
Huddinge
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Medivir business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Royalties from Xerclear/Zoviduo: Medivir receives royalties on sales of Xerclear/Zoviduo from GlaxoSmithKline and fixed royalties from Shijiazhuang Yuanmai Biotechnology for Chinese sales.
  2. Remetinostat licensing deal milestones and royalties: Outlicensed remetinostat to Biossil Inc. with potential payments up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.
  3. MIV-701/VBX-1000 royalties: Medivir retains significant financial upside through future royalties on net sales from Vetbiolix partnership plus substantial share of potential partnership payments from third-party collaborations.
  4. MBLI/MET-X revenue sharing: Medivir is entitled to a share of potential future revenue from INFEX Therapeutics development of MET-X for resistant bacteria.
  5. USP-7 revenue sharing: Exclusive global license to Ubiquigent for USP-7 program with agreed revenue sharing upon successful development or commercialization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Medivir product offering

Product offering

Core offering

Medivir is a clinical-stage pharmaceutical company that develops proprietary drug candidates in oncology and rare bone diseases, with lead assets fostrox (a liver-targeted nucleotide DNA polymerase inhibitor prodrug for hepatocellular carcinoma) and MIV-711 (a cathepsin K inhibitor for osteogenesis imperfecta and Legg-Calvé-Perthes disease). It also maintains a portfolio of out-licensed drug assets (Xerclear for labial herpes, Remetinostat for skin cancers, Birinapant for solid tumors, MBLI/MET-X for resistant bacteria, MIV-701/VBX-1000 for veterinary periodontitis, USP-7) that generate royalties and milestone payments from pharmaceutical partners.

Product overview

Medivir is a Swedish pharmaceutical company focused on developing innovative therapies in areas of high unmet medical need, primarily in oncology. The company's product portfolio consists of proprietary drug candidates in clinical development (fostrox for hepatocellular carcinoma and MIV-711 for osteogenesis imperfecta), projects available for licensing (Birinapant and USP-7), and outlicensed/commercialized products (Xerclear for herpes, MBLI/MET-X for infections, MIV-701 for canine periodontitis, and Remetinostat for skin cancers). Medivir operates either independently or through partnerships for drug development and commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fostroxacitabine bralpamide (fostrox) A liver-targeted oral nucleotide DNA polymerase inhibitor prodrug of troxacitabine that selectively delivers the active cell-killing compound to liver tumor cells while minimizing effects on normal liver cells. Being developed for second-line hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, and liver metastases, in combination with lenvatinib.
  • MIV-711 An oral cathepsin K inhibitor being developed for osteogenesis imperfecta (OI/brittle bone disease), Legg-Calvé-Perthes disease (LCPD), and osteoarthritis. Has demonstrated cartilage preservation and reduction of bone erosion in a Phase II osteoarthritis study and is positioned as a potential first approved pharmacological treatment for OI.
  • Birinapant An intravenous SMAC mimetic being developed for the treatment of solid tumors, intended to improve treatment response and prolong survival when combined with other pharmaceuticals. Out-licensed to IGM Biosciences.
  • USP-7

Quantifiable outcome

  • ORR of 24% with median DOR of 7 months in Phase 1b/2a fostrox + Lenvima study (21 patients)
  • +5 more outcomes

Companies that use Medivir

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Medivir technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Medivir partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Biossil Inc.coreStrategic or Co-development Partner · 1 October 2025Exclusive global licensing agreement for remetinostat development rights. Biossil, a Toronto-based AI-native drug developer, will develop remetinostat globally for cutaneous T-cell lymphoma and other skin cancers. Medivir entitled to up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.
  • Korean Cancer Study Group / Dr. Hong-Jae ChoncoreStrategic or Co-development Partner · 1 January 2025Collaboration for FLEX-HCC investigator-initiated randomized phase 2 study. Dr. Chon serves as primary investigator. Study to be conducted at 8 centers in Korea evaluating fostrox + Lenvima vs Lenvima monotherapy in second-line advanced HCC.
  • Eisai Co., Ltd.coreStrategic or Co-development Partner · 1 January 2024Clinical trial collaboration and supply agreement for evaluating fostrox in combination with Lenvima (lenvatinib) in a randomized, phase 2b study in second-line advanced liver cancer patients.
  • Ubiquigent LimitedminorStrategic or Co-development Partner · 1 February 2021Exclusive global license granted for USP-7 preclinical research program. Ubiquigent to develop and commercialize all related substances in all therapeutic indications in exchange for revenue sharing with Medivir upon successful development or commercialization. Unfortunately, funding challenges have made it impossible for Ubiquigent to continue operations.
  • IGM BiosciencesminorStrategic or Co-development Partner · 1 January 2021Exclusive licensing agreement for birinapant. Birinapant is a SMAC mimetic for treatment of solid tumors, acquired from TetraLogic Pharmaceuticals in 2016.
  • VetbiolixcoreStrategic or Co-development Partner · 1 January 2019Out-licensed MIV-701 (VBX-1000) for veterinary use in canine and feline periodontitis. Vetbiolix reported positive Proof-of-Concept results in April 2024 and published results in Frontiers in Veterinary Science in November 2025. Phase II study ongoing with results expected Q4 2026. Medivir retains significant financial upside through future royalties and partnership payment sharing.
  • INFEX Therapeutics (formerly AMR Centre)minorStrategic or Co-development Partner · 1 January 2017Out-licensed MBLI/MET-X program for addressing resistant bacteria. INFEX received QIDP designation from FDA in 2023 and European patent approval in August 2023. License agreement signed with Venus Remedies Ltd for clinical development in India. Medivir entitled to share of potential future revenue.
  • GlaxoSmithKlinecoreChannel Partner/ Reseller/ Distributor · 1 January 2009Out-licensed Xerclear marketing rights in Europe and rest of world (excluding China, Israel and South America where Medivir retained rights). Medivir receives royalties on sales of Xerclear/Zoviduo from GSK.
  • Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB)minorChannel Partner/ Reseller/ Distributor · 1 January 2009Out-licensed Xerclear rights for China market. After market registration and production in China, Medivir receives fixed royalty for each unit sold with guaranteed minimum sales during first three years on market.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Medivir competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Medivir social profiles

Digital presence

Medivir compliance and trust

Trust signal

Compliance5 records

Medivir financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medivir leadership team

Management profile

Number of profiles

Profiles8 records

Medivir funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medivir M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medivir

What does Medivir do?

Medivir is a clinical-stage pharmaceutical company that develops proprietary drug candidates in oncology and rare bone diseases, with lead assets fostrox (a liver-targeted nucleotide DNA polymerase inhibitor prodrug for hepatocellular carcinoma) and MIV-711 (a cathepsin K inhibitor for osteogenesis imperfecta and Legg-Calvé-Perthes disease). It also maintains a portfolio of out-licensed drug assets (Xerclear for labial herpes, Remetinostat for skin cancers, Birinapant for solid tumors, MBLI/MET-X for resistant bacteria, MIV-701/VBX-1000 for veterinary periodontitis, USP-7) that generate royalties and milestone payments from pharmaceutical partners.

Is Medivir a public or private company?

Medivir is a public company. It is classified as public and is currently operating.

When was Medivir founded?

Medivir was founded in 1988. It employs 11 to 50 people.

Where is Medivir based?

Medivir is headquartered in Huddinge, Sweden, in the Europe region.

How does Medivir make money?

Five revenue lines are on record. Royalties from Xerclear/Zoviduo is the primary driver. The others are remetinostat licensing deal milestones and royalties, MIV-701/VBX-1000 royalties, MBLI/MET-X revenue sharing and USP-7 revenue sharing.

Does Medivir have an API?

No public API is recorded for Medivir.

What industry is Medivir in?

Medivir's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingMedivir's MIV-711 wins FDA rare pediatric disease designation for osteogenesis imperfectaThe FDA granted Medivir's MIV-711 Rare Pediatric Disease Designation for osteogenesis imperfecta, with a proof-of-concept study planned. The drug already holds Orphan Drug Designation, and marketing approval could qualify it for a Priority Review Voucher. Medivir estimates a minimum USD 2.5 billion market for treatments addressing underlying bone fragility.The future of tradingFDA Grants Medivir's MIV-711 Rare Pediatric Disease Designation For Osteogenesis ImperfectaThe FDA granted Medivir's MIV-711 a rare pediatric disease designation for osteogenesis imperfecta. The drug may qualify for a priority review voucher, which has sold for $180-210 million in 2026.The future of tradingMedivir: FDA grants Medivir’s MIV-711 Rare Pediatric Disease Designation for Osteogenesis ImperfectaThe FDA granted Rare Pediatric Disease Designation to Medivir's MIV-711 for osteogenesis imperfecta, strengthening the drug ahead of its planned proof-of-concept study. The designation may lead to a Priority Review Voucher, which has sold for $180–210 million in 2026. Medivir estimates the market potential at a minimum of $2.5 billion.MarketScreenerMedivir granted combination patent and extends protection to 2044Medivir received a US patent for the fostrox-lenvatinib combination to treat hepatocellular carcinoma and liver metastases, with a 1,001-day extension extending protection to at least January 2044. The extension compensates for administrative delays, and the combination already has patent protection in the EU, Japan, Australia, and Canada.InvestegateMedivir granted US combination patent for fostrox plus lenvatinib, protection extended by almost three years to January 2044Medivir AB received USPTO grant of patent US12788771 for fostrox plus lenvatinib for liver cancer, with a 1,001-day Patent Term Adjustment extending protection to January 2044. The extension adds to previously granted patents in EU, Japan, Australia, and Canada, and the combination is being evaluated in the FLEX-HCC phase 2 study.The future of tradingMedivir converts 142,365 class C-shares into ordinary sharesMedivir converted 142,365 class C-shares into ordinary shares during September 2026 to deliver shares under LTIP 2023. As of Sept. 30, 2026, total shares were 626,487,237, including 624,179,439 ordinary shares, with remaining class C-shares totaling 2,307,798.